Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, has told DirectorsTalk about the appointment of Carsten Schroeder to the
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, has told DirectorsTalk that it has appointed Maarten Brusse, as Chief
Geoffrey Hamilton-Fairley, CEO of Oncimmune LON:ONC commented:“The ability to distinguish between malignant and benign lung nodules is a key challenge for physicians. This study, led by Pierre Massion, MD at
Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT(R) platform technology, announces that it has appointed Andrew Millet, BA MBA, FCA as
Oncimmune Holdings plc (LON:ONC) a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announced today that is has signed research agreements with Egybiotech, a private
Oncimmune Holdings plc (AIM: ONC.L) a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology, announces it has entered into three further distribution agreements in the
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii Oncimmune Holdings plc 2
Oncimmune Holdings PLC (LON:ONC), CEO Geoffrey Hamilton–Fairley caught up with DirectorsTalk to discuss it’s floatation on the AIM market, how the funds will be used and plans for expansion into
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
